EPIX Pharmaceuticals to Present at the CIBC World Markets 17th Annual Healthcare Conference
Posted on: Monday, 30 October 2006, 09:01 CST
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX) today announced that Michael G. Kauffman, M.D., Ph.D., chief executive officer of EPIX, will present at the CIBC World Markets 17th Annual Healthcare Conference on Monday, November 6, 2006 at 8:35 a.m. (EST) at the Waldorf-Astoria in New York, New York.
The presentation will be webcast live and can be accessed on the EPIX website, www.epixpharma.com, in the investor relations section. A replay will be available approximately three hours after the presentation and will be archived on the company's website for two weeks.
About EPIX
EPIX Pharmaceuticals is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products through the use of proprietary technology to better diagnose, treat and manage patients. The company has a blood-pool imaging agent approved and marketed in Europe (Vasovist™), approved in Australia and Switzerland, and five internally-discovered therapeutic and imaging drug candidates currently in clinical trials targeting conditions such as depression, Alzheimer's disease, cardiovascular disease and obesity. These drug candidates include EP-2104R, a novel thrombus imaging agent which has completed a Phase 2a trial, PRX-08066 in Phase 2 clinical development for pulmonary hypertension associated with chronic obstructive pulmonary disease, and PRX-03140, which has completed a Phase 1b clinical trial in Alzheimer's patients. EPIX also has collaborations with leading organizations, including Amgen, Cystic Fibrosis Foundation Therapeutics, and Schering AG (Germany). For more information about EPIX, please visit the company's website at www.epixpharma.com.
This news release contains express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, that are based on current expectations of management. These statements relate to, among other things, our expectations regarding the timing and content of corporate presentations. These statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. For additional information regarding these and other risks that we face, see the disclosure contained in our filings with the Securities and Exchange Commission.
Source: Business Wire
Related Articles
- Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
- TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
- EPIX Pharmaceuticals Initiates Phase 2b Program in Alzheimer's Disease
- Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate Its Diclofenac Patch for Mild to Moderate Pain
- Merck Initiates Phase II/III Clinical Trial of SLE
- Biothera Initiates Phase Ib/IIa Clinical Trial With Imprime PGG and Erbitux in Metastatic Colorectal Cancer Patients
- ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From Its U.S. Phase II/III Clinical Study Of Bepotastine
- Nutra Pharma Announces Final Approval to Begin Phase IIb Human Clinical Trial for the Treatment of Adrenomyeloneuropathy
- InterMune Enrolls 600th Patient in Phase III INSPIRE Clinical Trial
- Dendreon Completes Enrollment in Phase 3 PROTECT (P-11) Clinical Trial of Provenge in Early Stage Prostate Cancer
User Comments (0)

RSS Feeds